TuHURA Biosciences, Inc. (HURA) Stock Price, News, Quote & History

TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study

TuHURA Biosciences, Inc. (HURA) stock price, news, quote and history

TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma

Preliminary results: all 3 patients in a cancer study had tumors shrink; responses were ongoing at six months.

TuHURA Reports Initial Data Showing Partial Responses In First Three Metastatic Merkel Cell Carcinoma Patients Treated With Ifx-2.0 Plus Keytruda

12 Health Care Stocks Moving In Tuesday's After-Market Session

TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025

TuHURA Biosciences Secures US Patent For TBS-2025, Entitled ‘Anti-VISTA Antibodies And Uses Thereof’

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

TuHURA Biosciences Receives U.S. Patent For Administration Of DOR Antagonists

Citizens reiterates TuHURA Biosciences stock rating on AML therapy progress

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

HURA: Milestone Progression Over Next 12 Months

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord